Biohaven Ltd
Research Biohaven Ltd (BHVN) on Bullrun: market cap USD 2.25B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBHVN
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.25B
- Financial periodFY2025
- Net income-USD 738.82M
- Free cash flow-USD 610.15M
Valuation Snapshot
latest market cap is USD 2.25B.
About Biohaven Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy;
Frequently asked questions
What is Biohaven Ltd's market cap?
Biohaven Ltd's market capitalization is USD 2.25B.
What does Biohaven Ltd do?
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis;